Comparison of Diffusion-weighted MRI and MR Volumetry in the Evaluation of Early Treatment Outcomes After Preoperative Chemoradiotherapy for Locally Advanced Rectal Cancer
Overview
Authors
Affiliations
Purpose: To compare diffusion-weighted imaging (DWI) and magnetic resonance (MR) volumetry for predicting treatment outcomes of locally advanced rectal cancers with preoperative chemoradiotherapy (CRT).
Materials And Methods: This prospective study was approved by our Institutional Review Board. Thirty-four patients underwent three MR examinations: pre-CRT (before CRT), early CRT (2 weeks after CRT initiation), and post-CRT (before surgery). The tumor apparent diffusion coefficient (ADC), ADC increase rate, and volume reduction rate were compared between responders and nonresponders using three reference standards: downstaging, modified Response Evaluation Criteria in Solid Tumors (mRECIST), and tumor regression grade (TRG). For DWI and volumetry, differences between responders and nonresponders were assessed by receiver operating characteristic analysis.
Results: The median early tumor volume reduction rate of responders, subgrouped by downstaging and mRECIST (47.97% and 53.97%, respectively), was significantly higher than that of nonresponders (20.94% and 20.36%; P = 0.0024 and 0.0001, respectively), but there were no significant differences in pre-CRT ADC and early ADC increase rate using all references. When using the downstaging and mRECIST, the diagnostic performance of early tumor volume reduction rate (Az = 0.81 and 0.94, respectively) was higher than that of pre-CRT ADC (Az = 0.55 and 0.62; P = 0.033 and 0.007) and early ADC increase rate (Az = 0.58 and 0.64; P = 0.055 and 0.01) for predicting the treatment outcome. For TRG, there were no significant differences between DWI and volumetry.
Conclusion: Early tumor volume reduction rate at the second week after CRT initiation may be a better indicator than DWI based on the mean ADC measurements for predicting CRT treatment outcome.
Wada Y, Nishi M, Tokunaga T, Kashihara H, Takasu C, Yoshimoto T In Vivo. 2025; 39(2):927-935.
PMID: 40010977 PMC: 11884458. DOI: 10.21873/invivo.13897.
MRI Predicts Residual Disease and Outcomes in Watch-and-Wait Patients with Rectal Cancer.
Williams H, Omer D, Thompson H, Lin S, Verheij F, Miranda J Radiology. 2024; 312(3):e232748.
PMID: 39225603 PMC: 11427875. DOI: 10.1148/radiol.232748.
Gao P, Lu N, Liu W Front Oncol. 2023; 13:1031581.
PMID: 36741013 PMC: 9890074. DOI: 10.3389/fonc.2023.1031581.
Bourbonne V, Schick U, Pradier O, Visvikis D, Metges J, Badic B Cancers (Basel). 2023; 15(2).
PMID: 36672381 PMC: 9857080. DOI: 10.3390/cancers15020432.
Chen L, Liu X, Zhang W, Qin S, Wang Y, Lin J Ann Transl Med. 2022; 10(12):666.
PMID: 35845508 PMC: 9279805. DOI: 10.21037/atm-22-2418.